Global Viral Vector Development Service 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01254992

Publication Date:

January 24, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Viral Vector Development Service market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Viral Vector Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Viral Vector Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Viral Vector Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Viral Vector Development Service players cover UJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, UniQure, MassBiologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淰iral Vector Development Service Industry Forecast鈥� looks at past sales and reviews total world Viral Vector Development Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector Development Service sales for 2025 through 2031. With Viral Vector Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Development Service industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Viral Vector Development Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Development Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Development Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Development Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Retroviral Vectors
Lentiviral Vectors
Adenoviral Vectors
Adeno-associated Viral Vectors
Others Viral Vectors
Segmentation by Application:
Pharmaceutical Manufacturers
Biotechnology Companies
Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
UJIFILM Diosynth Biotechnologies
Sanofi
Spark Therapeutics
UniQure
MassBiologics
FinVector
Thermo Fisher Scientific (Brammer Bio)
Cell and Gene Therapy Catapult
Cobra Biologics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Viral Vector Development Service 麻豆原创 Size (2020-2031)
2.1.2 Viral Vector Development Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Viral Vector Development Service by Country/Region (2020, 2024 & 2031)
2.2 Viral Vector Development Service Segment by Type
2.2.1 Retroviral Vectors
2.2.2 Lentiviral Vectors
2.2.3 Adenoviral Vectors
2.2.4 Adeno-associated Viral Vectors
2.2.5 Others Viral Vectors
2.3 Viral Vector Development Service 麻豆原创 Size by Type
2.3.1 Viral Vector Development Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Viral Vector Development Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Viral Vector Development Service Segment by Application
2.4.1 Pharmaceutical Manufacturers
2.4.2 Biotechnology Companies
2.4.3 Research Institutes
2.5 Viral Vector Development Service 麻豆原创 Size by Application
2.5.1 Viral Vector Development Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Viral Vector Development Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Viral Vector Development Service 麻豆原创 Size by Player
3.1 Viral Vector Development Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Viral Vector Development Service Revenue by Player (2020-2025)
3.1.2 Global Viral Vector Development Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Viral Vector Development Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Viral Vector Development Service by Region
4.1 Viral Vector Development Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Viral Vector Development Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Viral Vector Development Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Viral Vector Development Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Viral Vector Development Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Viral Vector Development Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Viral Vector Development Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Viral Vector Development Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector Development Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Viral Vector Development Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Viral Vector Development Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Viral Vector Development Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Viral Vector Development Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Viral Vector Development Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Viral Vector Development Service by Region (2020-2025)
8.2 Middle East & Africa Viral Vector Development Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Viral Vector Development Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Viral Vector Development Service 麻豆原创 Forecast
10.1 Global Viral Vector Development Service Forecast by Region (2026-2031)
10.1.1 Global Viral Vector Development Service Forecast by Region (2026-2031)
10.1.2 Americas Viral Vector Development Service Forecast
10.1.3 APAC Viral Vector Development Service Forecast
10.1.4 Europe Viral Vector Development Service Forecast
10.1.5 Middle East & Africa Viral Vector Development Service Forecast
10.2 Americas Viral Vector Development Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Viral Vector Development Service Forecast
10.2.2 Canada 麻豆原创 Viral Vector Development Service Forecast
10.2.3 Mexico 麻豆原创 Viral Vector Development Service Forecast
10.2.4 Brazil 麻豆原创 Viral Vector Development Service Forecast
10.3 APAC Viral Vector Development Service Forecast by Region (2026-2031)
10.3.1 China Viral Vector Development Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Viral Vector Development Service Forecast
10.3.3 Korea 麻豆原创 Viral Vector Development Service Forecast
10.3.4 Southeast Asia 麻豆原创 Viral Vector Development Service Forecast
10.3.5 India 麻豆原创 Viral Vector Development Service Forecast
10.3.6 Australia 麻豆原创 Viral Vector Development Service Forecast
10.4 Europe Viral Vector Development Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Viral Vector Development Service Forecast
10.4.2 France 麻豆原创 Viral Vector Development Service Forecast
10.4.3 UK 麻豆原创 Viral Vector Development Service Forecast
10.4.4 Italy 麻豆原创 Viral Vector Development Service Forecast
10.4.5 Russia 麻豆原创 Viral Vector Development Service Forecast
10.5 Middle East & Africa Viral Vector Development Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Viral Vector Development Service Forecast
10.5.2 South Africa 麻豆原创 Viral Vector Development Service Forecast
10.5.3 Israel 麻豆原创 Viral Vector Development Service Forecast
10.5.4 Turkey 麻豆原创 Viral Vector Development Service Forecast
10.6 Global Viral Vector Development Service Forecast by Type (2026-2031)
10.7 Global Viral Vector Development Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Viral Vector Development Service Forecast
11 Key Players Analysis
11.1 UJIFILM Diosynth Biotechnologies
11.1.1 UJIFILM Diosynth Biotechnologies Company Information
11.1.2 UJIFILM Diosynth Biotechnologies Viral Vector Development Service Product Offered
11.1.3 UJIFILM Diosynth Biotechnologies Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 UJIFILM Diosynth Biotechnologies Main Business Overview
11.1.5 UJIFILM Diosynth Biotechnologies Latest Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Viral Vector Development Service Product Offered
11.2.3 Sanofi Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Sanofi Main Business Overview
11.2.5 Sanofi Latest Developments
11.3 Spark Therapeutics
11.3.1 Spark Therapeutics Company Information
11.3.2 Spark Therapeutics Viral Vector Development Service Product Offered
11.3.3 Spark Therapeutics Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Spark Therapeutics Main Business Overview
11.3.5 Spark Therapeutics Latest Developments
11.4 UniQure
11.4.1 UniQure Company Information
11.4.2 UniQure Viral Vector Development Service Product Offered
11.4.3 UniQure Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 UniQure Main Business Overview
11.4.5 UniQure Latest Developments
11.5 MassBiologics
11.5.1 MassBiologics Company Information
11.5.2 MassBiologics Viral Vector Development Service Product Offered
11.5.3 MassBiologics Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 MassBiologics Main Business Overview
11.5.5 MassBiologics Latest Developments
11.6 FinVector
11.6.1 FinVector Company Information
11.6.2 FinVector Viral Vector Development Service Product Offered
11.6.3 FinVector Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 FinVector Main Business Overview
11.6.5 FinVector Latest Developments
11.7 Thermo Fisher Scientific (Brammer Bio)
11.7.1 Thermo Fisher Scientific (Brammer Bio) Company Information
11.7.2 Thermo Fisher Scientific (Brammer Bio) Viral Vector Development Service Product Offered
11.7.3 Thermo Fisher Scientific (Brammer Bio) Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Thermo Fisher Scientific (Brammer Bio) Main Business Overview
11.7.5 Thermo Fisher Scientific (Brammer Bio) Latest Developments
11.8 Cell and Gene Therapy Catapult
11.8.1 Cell and Gene Therapy Catapult Company Information
11.8.2 Cell and Gene Therapy Catapult Viral Vector Development Service Product Offered
11.8.3 Cell and Gene Therapy Catapult Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Cell and Gene Therapy Catapult Main Business Overview
11.8.5 Cell and Gene Therapy Catapult Latest Developments
11.9 Cobra Biologics
11.9.1 Cobra Biologics Company Information
11.9.2 Cobra Biologics Viral Vector Development Service Product Offered
11.9.3 Cobra Biologics Viral Vector Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Cobra Biologics Main Business Overview
11.9.5 Cobra Biologics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.